5xcs
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide== | |
| + | <StructureSection load='5xcs' size='340' side='right' caption='[[5xcs]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[5xcs]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XCS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5XCS FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5xcq|5xcq]], [[5xcr|5xcr]], [[5xct|5xct]], [[5xcu|5xcu]], [[5xcv|5xcv]], [[5xcx|5xcx]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5xcs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5xcs OCA], [http://pdbe.org/5xcs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5xcs RCSB], [http://www.ebi.ac.uk/pdbsum/5xcs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5xcs ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Antibody fragments are frequently used as a "crystallization chaperone" to aid structural analysis of complex macromolecules that are otherwise crystallization resistant, but conventional fragment formats have not been designed for this particular application. By fusing an anti-parallel coiled-coil structure derived from the SARAH domain of human Mst1 kinase to the variable region of an antibody, we succeeded in creating a novel chimeric antibody fragment of approximately 37 kDa, termed "Fv-clasp," which exhibits excellent crystallization compatibility while maintaining the binding ability of the original IgG molecule. The "clasp" and the engineered disulfide bond at the bottom of the Fv suppressed the internal mobility of the fragment and shielded hydrophobic residues, likely contributing to the high heat stability and the crystallizability of the Fv-clasp. Finally, Fv-clasp antibodies showed superior "chaperoning" activity over conventional Fab fragments, and facilitated the structure determination of an ectodomain fragment of integrin alpha6beta1. | ||
| - | + | Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability.,Arimori T, Kitago Y, Umitsu M, Fujii Y, Asaki R, Tamura-Kawakami K, Takagi J Structure. 2017 Sep 6. pii: S0969-2126(17)30264-2. doi:, 10.1016/j.str.2017.08.011. PMID:28919443<ref>PMID:28919443</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| + | <div class="pdbe-citations 5xcs" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Arimori, T]] | ||
| + | [[Category: Takagi, J]] | ||
| + | [[Category: Antibody fragment]] | ||
| + | [[Category: Fv-clasp]] | ||
| + | [[Category: Immune system]] | ||
Revision as of 09:08, 4 October 2017
Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide
| |||||||||||
